Keeps Biopharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Keeps Biopharma is a pharmaceutical and biotechnology company listed on KOSDAQ, South Korea's tech-focused small-cap exchange.
It operates in the health-care sector, developing and supplying pharmaceutical or biopharmaceutical products, though the available filing text does not detail specific product lines or end-markets. The company is currently loss-making while its revenue has been growing year over year.
Summary is AI-generated and may contain errors · figures from DART filings
Keeps Biopharma in five facts
What does Keeps Biopharma do?
Keeps Biopharma is a pharmaceutical and biotechnology company listed on KOSDAQ, South Korea's tech-focused small-cap exchange.
Where is Keeps Biopharma listed and in which sector?
Keeps Biopharma (Korean name: 킵스파마) trades under KRX code 256940 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Keeps Biopharma?
Its market capitalisation was US$85.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Keeps Biopharma's latest annual revenue and operating profit?
For fiscal year 2025, Keeps Biopharma reported revenue of US$128.4M, operating profit of US$1.2M and a net loss of US$7.8M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 33.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 16
- DisclosureSep 11
- [Amended] Material event report (convertible bonds)
Keeps Biopharma updated the terms of convertible bonds to raise US$20.9M, about 21.5% of its market value.
Capital raise · Jul 6 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Keeps Biopharma reported consolidated results for FY2025: revenue of US$116M (+33.4% year on year), operating profit of US$1.07M (−74.7% year on year) and a net loss of US$7.87M (from a profit a year earlier).
Earnings · Mar 13